Dermatology News

Dermatology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kopp HG et al. - Novel compounds such as bevacizumab, multi-tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, imatinib, and the thrombospondin agonist ABT 510 represent attractive partners for the above-mentioned cytostatic agents, or may even be effective single agents in the clinically advanced setting.

Related Articles

Postirradiation Sarcoma: Clinicopathologic Features and Role of Chemotherapy in the Treatment Strategy
Sarcoma, 11/23/09    Relevance Score: 92%

Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas
Modern Pathology, 11/11/09    Relevance Score: 92%

Histiocytic sarcoma with interdigitating dendritic cell differentiation: A case report with fine needle aspiration cytology and review of literature
Diagnostic Cytopathology, 10/28/09    Relevance Score: 90%

Skeletal metastasis from sarcoma: a report of three cases
European Journal of Orthopaedic Surgery & Traumatology, 10/23/09    Relevance Score: 89%

Alveolar soft-part sarcoma of the tongue in a 17-month-old
ENT Journal, 10/19/09    Relevance Score: 89%

Today in Dermatologic Oncology...keeping you current

Small and Medium-Sized Congenital Nevi in Children: A Comparison of the Costs of Excision and Long-Term Follow-Up
Dermatologic Surgery, 12/09/09

Developing the readiness to alter sun-protective behaviour questionnaire (RASP-B)
Cancer Epidemiology, 12/09/09

Creation and test of a questionnaire for self-assessment of melanoma risk factors
European Journal of Cancer Prevention, 12/09/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address